RESULTS OF THE STRATEGIC PRIORITY REVIEW CONDUCTED BY THE EXECUTIVE COMMITTEE IN NOVEMBER 2017

2018: FOCUS ON MEDICAL CANNABIS FOR COMPANION ANIMALS

Evry (France), on the 9th of January 2018 – GOUR MEDICAL (CH0342399851 MLGML/Shares eligible for the PEA-PME/share savings plan), a company specialized in the development and commercialisation of innovative veterinary solutions for senior pets, has published today the results of the strategic review conducted by its Executive Committee in November 2017.

Serge Goldner, the CEO of GOUR MEDICAL, declared: “Our decision to focus our business plan on medical cannabis for senior pets rests on the results of the strategic review conducted towards the end of the 2017 financial year, and on highly promising developments in the pain management market and in treatments that improve quality of life for animals, based on innovative solutions for senior pets”.

UNIQUE POSITIONING REGARDING PATHOLOGIES LINKED TO THE AGING OF COMPANION ANIMALS

Since its creation in 2014 in Switzerland, GOUR MEDICAL has proven its ability to sign exclusive and international licencing agreements with leading pharmaceutical companies, mostly for cutting-edge molecules pertaining to pain and anxiety management in household pets, namely with:

  • IDORSIA-IDIA (SWX), for Gour-713, an orexin receptor antagonist;
  • IDEXX LAB IDXX (NASDAQ), for Gour-419, an anti-IgE antibody aimed at treating atopic dermatitis;
  • SOLMIC RESEARCH GmbH, for Gour-153, a pain and stress relief food supplement based on a proprietary formulation that improves the bioavailability of cannabidiol.

Since late 2016, GOUR MEDICAL is listed on Euronext Access Paris (CH0342399851 MLGML)

FAST-PACED DYNAMICS OF THE FIELD OF ANIMAL HEALTH AND PAIN MANAGEMENT

In 2017, Americans spent 69 billion dollars on their household pets1. With life expectancy for pets and their owners getting longer and longer and in addition to the growing interest they have in their pets, the companion animal health market has shown dynamic and resilient growth (CAGR 2016-2025 of 5.4%)2.  

The pain management market for remedies represented 400 million dollars throughout the world3 in 2017, 170 of which are in Europe4.

A US stock exchange index especially made up of companies working to improve pet health has increased by 19% since the start of 2017. Comparatively, the growth of the S&P 500 index only reached 8.5%5.

GOUR MEDICAL WILL BE FOCUSING ON MEDICAL CANNABIS FOR SENIOR PETS AND SETTING-UP R&D TEAMS IN FRANCE AND ISRAEL

A number of large-scale agreements were signed in 2017 supporting GOUR MEDICAL’s cannabidiol-based positioning: acquisition by Zoetis of NextVet Biopharma, and of Animalcare Group by Ecuphar NV in July 2017, launched in November 2017 of the Anabidiol range (CBD-based food supplements for pets) by Virbac following their agreement with Cresopharma6. GOUR MEDICAL has therefore benefited from significant exposure throughout the past financial year, and has gained keen interest from both French and foreign investors.

These various transactions convinced the Executive Committee to refocus GOUR MEDICAL’s strategic priorities for the 2018 financial year, to value its background and expertise in medical cannabis used in companion animals (cannabidiol and terpenes),to review the Company’s organization, and to transfer the company’ headquarters to France.

GOUR MEDICAL will set up an R&D team in France, as well as a medical cannabis team based in Israel, this would gain easier access to the medical, agricultural engineering and technological expertise pertaining to medical cannabis in Israel – a country with cutting-edge research and development in this specific field.

OUR GOAL:  TO BE THE KEY COMPANY IN INNOVATIVE PAIN TREATMENTS AND THE IMPROVEMENT OF QUALITY OF LIFE FOR SENIOR PETS

The international market for disease treatment in pets suffering from age-related pathologies is currently estimated at 3.5 billion dollars7. The treatments are naturally fed to pets which are extending their life span, making pathologies more likely to occur.

Due to the legalisation of medical cannabis for humans in 29 American States, and several European countries such as Germany, as well as the scheduled legalisation of medical cannabis in Canada in July 2018, medical treatments made using Cannabidiol (CBD) will be accessible in 25 countries throughout the world8.

GOUR MEDICAL intends to leverage its knowledge of medical cannabis-based treatments (cannabidiol and terpenes – which are natural products with no side effects or psychoactive effects, complying with regulations for veterinary/nutraceutical products) to commercialize – in a rigorous and controlled manner – a range of products adapted to each pathology, under several delivery systems and after having verified the entire manufacturing, packaging and marketing process.

These products will be used to address chronic pathologies pertaining to pet aging, such as pain caused by arthritis, stress, anxiety and end-of-life support treatments.

Given the sector’s recent positive developments and the progress to search for strategic partnerships, GOUR MEDICAL aims to launch a commercial pilot targeting the last quarter of 2018.

Next publication: Friday 12 January, 2018 – after end of day trading:

Eligibility of GOUR MEDICAL’s shares with the PEA-PME/share savings plan

 

Further information available on GOUR MEDICAL’s website:

http://www.gour-medical.com                    

1 Source: Les Echos 31/08/2017: https://www.lesechos.fr/31/08/2017/lesechos.fr/030518882565_chats–chiens–hamsters—-les-nouveaux-meilleurs-amis-de-wall-street.htm

2: Source: Market Watch 2016

3:  Zoetis (press release announcing the acquisition of NextVet Biopharma on 31/07/2017 http://news.zoetis.com/press-release/animalhealth/zoetis-completes-acquisition-nexvet-biopharma)

4: CEESA International Sales Survey (CISS)

5: Les Echos 31/08/2017 + Bloomberg: https://www.bloomberg.com/news/articles/2017-08-18/pet-stocks-beat-the-market-as-animal-owners-open-their-wallets

6: Zoetis/NextVet Biopharma: http://news.zoetis.com/press-release/animalhealth/zoetis-completes-acquisition-nexvet-biopharma; Animalcare/Ecuphar NV: https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=12059157; Cresopharma/Virbac:

https://finfeed.com/biotech/cph/creso-makes-european-market-debut -commercial-launch-first-animal-product/20171115/:

7: Source: ERS Healthcare Innovation July 2015

8: Source: Le Monde 17/11/2017

About Gour Medical

Gour Medical is a company specialised in the development and commercialisation of innovative veterinary solutions for treating major pathologies linked to pet aging. Its unique positioning is namely based on the use of molecules and nutraceuticals with proven medical virtues and new delivery systems. Its first product soon to be commercialised aims for long-term pain management, thanks to a formulation based on industrial hemp extract, presenting no psychoactive effects.

GOUR MEDICAL is listed on Euronext Access (CH0342399851 MLGML). Gour Medical’s shares are eligible for the PEA-PME/share savings plan.

 

 

Contacts

animaux thérapeutiques

 

 

Serge Goldner

CEO

contact@gour-medical.com


logo

FINANCIAL COMMUNICATION

Edouard de Maissin

Analyst & Investor Relations

Tel.: +33 1 42 46 11 73

edouarddemaissin@ciib.fr

 

 

Download PDF version of this PR